Lowell Anthony, MD
Enriched profileProfessor of Medicine; Chief, Division of Medical Oncology; Director, Neuroendocrine Clinical Oncology Program · University of Kentucky Markey Cancer Center
Lowell Anthony is Professor of Medicine; Chief, Division of Medical Oncology; Director, Neuroendocrine Clinical Oncology Program at University of Kentucky Markey Cancer Center. OpenAlex indexes 294 publications with 6,742 citations (h-index 37); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 18 Oct 2026
Lowell B. Anthony, M.D., is Professor of Medicine at University of Kentucky Markey Cancer Center. The public record shows 294 publications with 6,742 citations (h-index 37), centered on Neuroendocrine Tumor Research Advances, Pituitary Gland Disorders and Treatments, Radiopharmaceutical Chemistry and Applications. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 6 companies, 1 NIH-funded awards (2018–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Neuroendocrine Tumor Research Advances
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 4 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 89.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Sponsor: Perspective Therapeutics
Industry payments
Updated 18 Oct 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year202514 payments
- HISTOSONICS, INC.Program year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
31.5%Kinase inhibitor25.4%Everolimus56%Cabometyx34%Sunitinib Malate10%Part D<11 patientsCytochrome P450 17A1 Inhibitor3.7%Abiraterone Acetate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
27.6%Serotonin-3 Receptor Antagonist11%Ondansetron Hcl100%Part D≥26 patientsCorticosteroid7.1%Prednisone100%Part D≥15 patients+ 3 more classes in this area
Nervous system
26.6%Opioid Agonist12.8%Oxycodone Hcl100%Part D≥22 patientsBenzodiazepine8.5%Lorazepam62%Alprazolam38%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
1 NIH research award on record, funded 2018–2026 per NIH RePORTER. The latest:
Congress activity
Updated 18 Oct 2026
79 congress contributions (2004–2026) across AACR, ASCO, ESMO per OpenAlex. The most recent:
- A phase 1 first-in-human, dose-escalation and -expansion study of RYZ401, a novel radiopharmaceutical therapy (RPT) labeled with actinium-225 ( 225 Ac), in patients with neuroendocrine tumors (NETs) and other solid tumors expressing somatostatin receptors (SSTRs).
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)- 01Consensus Guidelines for the Management and Treatment of Neuroendocrine TumorsArticle580 citations2013
- 02NANETS Treatment GuidelinesArticle573 citations2010
- 03
- 04
- 0590Y-Edotreotide for Metastatic Carcinoid Refractory to OctreotideArticle306 citations2010
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/lowell-anthony-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Facebook
carcinoid.org/news/facebook-live-program-on-carcinoid-syndrome-managing-breakthrough-symptoms
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →carcinoid.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Vanderbilt University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ukhealthcare.uky.edu ↗ - BS
King College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →expertinstitute.com ↗
Editorial & leadership roles
journal and society appointments- Fellow
American College of Physicians
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ukhealthcare.uky.edu ↗ - Committee Member
American Society of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertinstitute.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nanets.net ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uknow.uky.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uknow.uky.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH